Two Doses Of Novel Intranasal COVID-19 Vaccine Induce Poly-Antigenic Immune Response, Study Finds

HealthDay (10/17, Gotkine) reports, “Two doses of a novel intranasal live-attenuated COVID-19 vaccine, CoviLiv, induce poly-antigenic immune response, according to a study presented at” IDWeek 2023. In the trial, “researchers found that all participants e...